الفهرس 
Primary Pterygium
Mitomycin COnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
Pterygium is a triangular growth of fibrovascular tissue that extends from the conjunctive onto the cornea. The overall prevalence range from 0.7 to 31% in various population around the world. Many theories have been proposed to explain the etiology of the pterygium which was almostly considered to be a keratoconjunctival degeneration. However, recently, the most accepted theory is that the pterygium is considered to be due to limbal stem cell dysfunction.The most difficult problem faced in the management of pterygia is their frequent and aggressive recurrence following surgical removal. There is no surgical procedure for pterygium removal to be universally accepted as being perfect. With subsequent recurrences, the rate of formation is quicker, the inflammatory process is more intense, the subsequent fibroses is more severe and the recurrent pterygium becomes larger than the original one. Many workers have tried different techniques to minimize the incidence of recurrence with little or no complications. Aiming to minimize the postoperative high recurrence rate of pterygium, many adjunctive therapies have been tried includes: β- irradiation, thiotepa, mitomycin C, cyro, cyanoacrylate, corticosteroids, Excimer laser and argon laser photocoagulation.The aim of this study is to evaluate the efficacy of preoperative subconjunctival injection of mitomycin C on the postoperative outcome of primary pterygium excision with AMT.